FDA Chief Counsel, Ad Division Concur On 94% Of Violation Letters, Troy Says
Executive Summary
FDA's Office of the Chief Counsel concurs with 94% of the Division of Drug Marketing, Advertising & Communications' enforcement letters, Chief Counsel Daniel Troy said
You may also be interested in...
FDA Approps Amendment Targets Chief Counsel Troy; Pfizer Ties Challenged
The House FDA appropriations bill cuts $500,000 from the budget of the chief counsel's office in response to actions taken by Chief Counsel Daniel Troy
Way To Whack A Mole? FDA Warning Letters To Seek Recurrent “Bad Actors”
FDA plans to provide more specific guidance to industry on what constitutes deceptive advertising, Commissioner Mark McClellan said
Way To Whack A Mole? FDA Warning Letters To Seek Recurrent “Bad Actors”
FDA plans to provide more specific guidance to industry on what constitutes deceptive advertising, Commissioner Mark McClellan said